MGCD 290

Drug Profile

MGCD 290

Alternative Names: Antifungal Hos2 histone deacetylase (HDAC) enzyme inhibitor (MGCD290); MG-3290; MGCD-290

Latest Information Update: 28 Mar 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MethylGene
  • Class Antifungals; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Mycoses; Vulvovaginal candidiasis

Most Recent Events

  • 28 Mar 2014 MGCD 290 is available for licensing in World as of 28 Mar 2014. http://mirati.com/
  • 31 Dec 2013 Suspended - Phase-I for Mycoses (in volunteers) in Canada (PO)
  • 31 Dec 2013 Suspended - Phase-II for Vulvovaginal candidiasis (combination therapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top